The purpose of this study is to evaluate how effective quetiapine versus placebo is when added to an existing therapy, in reducing the symptoms of PTSD.

Official Title

A Multicentre, Parallel Group, Randomised, Double Blind, Placebo Controlled Study of the Use of Quetiapine as an Add on Therapy in the Treatment of Post Traumatic Stress Disorder

Conditions

Post-Traumatic Stress Disorder

Study Type

Interventional

Study Design

Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Efficacy Study

Further Details

Primary Outcome Measures:

  • Clinical Administered PTSD Scale (CAPS2)

Secondary Outcome Measures:

  • Hamilton Depression Scale (HAM-D)
  • Hamilton Anxiety Scale (HAM-A)
  • Posttraumatic Stress Disorder Checklist (PCL)
  • Clinical Global Impressions (CGI)

Study Start

December 2004

Eligibility & Criteria

  • Ages Eligible for Study: 18 Years – 65 Years
  • Genders Eligible for Study: Both

Inclusion Criteria:

  • Hospitalised and non-hospitalised patients / Veteran or Civilian / Have had symptoms of PTSD for a minimum of 12 months prior to giving consent to the study

Exclusion Criteria:

  • History of psychotic condition / quetiapine or other anti-psychotics not worked previously / Taking prohibited medications (mood stabilizers / substance abuse)

Total Enrolment

90

Contact Details

  • Brisbane, Queensland, Australia; Recruiting
  • Adelaide, South Australia, Australia; Recruiting
  • Melbourne, Victoria, Australia; Recruiting

Contact AstraZeneca for more information